Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
暂无分享,去创建一个
L. Recht | T. Mikkelsen | M. Weller | A. Brandes | T. Cloughesy | M. Westphal | K. Hopkins | C. Balañà | O. Chinot | G. Finocchiaro | T. Sandmann | D. Macdonald | H. Koeppen | D. Shames | J. Bruey | S. Phan | E. Pineda | C. Belda-Iniesta | W. Verret | Bo Liu | C. Bais
[1] R. Bourgon,et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Reifenberger,et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.
[3] R. Vernhout,et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.
[4] H. Koeppen,et al. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development , 2014, Oncotarget.
[5] I. Wistuba,et al. Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit , 2014, Clinical Cancer Research.
[6] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[7] K. Hoang-Xuan,et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[8] M. Fabrini,et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology) , 2013, Journal of Neuro-Oncology.
[9] J. Simes,et al. A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). , 2013 .
[10] A. Zhu,et al. Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.
[11] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[12] G. Mills,et al. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Abernethy,et al. MET and ALK in glioblastoma multiforme (GBM): Comparison of IHC and FISH. , 2012 .
[14] H. Friedman,et al. Bevacizumab and daily temozolomide for recurrent glioblastoma , 2012, Cancer.
[15] F. Marincola,et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma , 2011, Proceedings of the National Academy of Sciences.
[16] D. Crooks,et al. Biology, genetics and imaging of glial cell tumours. , 2011, The British journal of radiology.
[17] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[19] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] John A Butman,et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] T. Mikkelsen,et al. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue , 2007, Laboratory Investigation.
[23] M. Westphal,et al. A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo , 2006, Clinical Cancer Research.
[24] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[25] P. Brenchley,et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas , 2001, Histopathology.
[26] E. Hudson,et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. , 1997, Cancer research.
[27] G. Bergers,et al. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. , 2013, CNS oncology.
[28] Michael Weller,et al. Standards of care for treatment of recurrent glioblastoma--are we there yet? , 2013, Neuro-oncology.
[29] Anupama E. Gururaj,et al. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells. , 2013, Neoplasia.
[30] G. Reifenberger,et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.